The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck

Oral Oncology

Volumn 50, Issue 7, 2014, Pages 627-632

  Zandberg, Dan P ^a,b   Strome, Scott E ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

B7 H1; Head and neck; Immunotherapy; PD 1; PD L1; Squamous

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 936659; MEDI 4736; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; APOPTOSIS; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER TISSUE; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DISEASE FREE SURVIVAL; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MOLECULAR BIOLOGY; MYELOID DERIVED SUPPRESSOR CELL; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; TISSUE MICROARRAY; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD274; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION;

EID: 84901770708     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.04.003     Document Type: Review

References (74)

1. J.B. Vermorken, and P. Specenier Optimal treatment for recurrent/metastatic head and neck cancer Ann Oncol 21 Suppl 7 2010 vii252 61
2. J.J. Grau, M. Caballero, E. Verger, M. Monzo, and J.L. Blanch Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients Acta Otolaryngol 129 11 2009 1294 1299
3. J.B. Vermorken, J. Trigo, and R. Hitt et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 16 2007 2171 2177
4. R.S. Herbst, M. Arquette, and D.M. Shin et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck J Clin Oncol 23 24 2005 5578 5587
5. J. Baselga, J.M. Trigo, and J. Bourhis et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck J Clin Oncol 23 24 2005 5568 5577
6. G. Numico, and M. Merlano Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer Ann Oncol 13 2 2002 331 333
7. B.C. Cho, K.C. Keum, and S.J. Shin et al. Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck Cancer Chemother Pharmacol 65 1 2009 27 32
8. S.A. Saddoughi, E. Garrett-Mayer, and U. Chaudhary et al. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C(1)(8)-ceramide as a novel biomarker for monitoring response Clin Cancer Res 17 18 2011 6097 6105
9. J.D. Raguse, H.J. Gath, J. Bier, H. Riess, and H. Oettle Gemcitabine in the treatment of advanced head and neck cancer Clin Oncol (R Coll Radiol) 17 6 2005 425 429
10. J.E. Bauman, H. Arias-Pulido, and S.J. Lee et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma Oral Oncol 2013
11. E.O. Hanrahan, M.S. Kies, and B.S. Glisson et al. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck Am J Clin Oncol 32 3 2009 274 279
12. S. Zenda, Y. Onozawa, N. Boku, Y. Iida, M. Ebihara, and T. Onitsuka Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) Jpn J Clin Oncol 37 7 2007 477 481
13. S.E. Strome, E.A. Sausville, and D. Mann A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects Oncologist 12 9 2007 1084 1095
14. R.M. Srivastava, S.C. Lee, and P.A. Andrade Filho et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients Clin Cancer Res 19 7 2013 1858 1872
15. H. Dong, S.E. Strome, and D.R. Salomao et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 8 2002 793 800
16. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion [see comments] Nat Med 5 12 1999 1365 1369
17. S. Wang, J. Bajorath, D.B. Flies, H. Dong, T. Honjo, and L. Chen Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction J. Exp. Med. 197 9 2003 1083 1091
18. F. Hirano, K. Kaneko, and H. Tamura et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 3 2005 1089 1096
19. T. Azuma, S. Yao, G. Zhu, A.S. Flies, S.J. Flies, and L. Chen B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells Blood 111 7 2008 3635 3643
20. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 2455 2465
21. S.L. Topalian, F.S. Hodi, and J.R. Brahmer et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
22. A. Ribas Tumor immunotherapy directed at PD-1 N Engl J Med 366 26 2012 2517 2519
23. W. Lin, C.J. Voskens, and X. Zhang et al. Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies Blood 112 3 2008 699 707
24. L. Chen Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity Nat Rev Immunol 4 5 2004 336 347
25. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
26. B. Seliger, and D. Quandt The expression, function, and clinical relevance of B7 family members in cancer Cancer Immunol Immunother 61 8 2012 1327 1341
27. Y. Ohigashi, M. Sho, and Y. Yamada et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clin Cancer Res 11 8 2005 2947 2953
28. C. Wu, Y. Zhu, J. Jiang, J. Zhao, X.G. Zhang, and N. Xu Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance Acta Histochem 108 1 2006 19 24
29. J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 10 15 2004 5094 5100
30. H. Ghebeh, A. Tulbah, and S. Mohammed et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells Int J Cancer 121 4 2007 751 758
31. J. Nakanishi, Y. Wada, K. Matsumoto, M. Azuma, K. Kikuchi, and S. Ueda Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers Cancer Immunol Immunother 56 8 2007 1173 1182
32. C.S. Brandt, M. Baratin, and E.C. Yi et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans J Exp Med 206 7 2009 1495 1503
33. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 12 1999 1365 1369
34. C. Berthon, V. Driss, and J. Liu et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors Cancer Immunol Immunother 59 12 2010 1839 1849
35. C.M. Wilke, S. Wei, L. Wang, I. Kryczek, J. Kao, and W. Zou Dual biological effects of the cytokines interleukin-10 and interferon-gamma Cancer Immunol Immunother 60 11 2011 1529 1541
36. X. Frigola, B.A. Inman, and C.M. Lohse et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma Clin Cancer Res 17 7 2011 1915 1923
37. Y.F. Xing, Z.L. Zhang, M.H. Shi, Y. Ma, and Y.J. Chen The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications Zhonghua Jie He He Hu Xi Za Zhi 35 2 2012 102 106
38. J.J. Park, R. Omiya, and Y. Matsumura et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance Blood 116 8 2010 1291 1298
39. D.L. Barber, E.J. Wherry, and D. Masopust et al. Restoring function in exhausted CD8 T cells during chronic viral infection Nature 439 7077 2006 682 687
40. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2 2012 207 212
41. C. Badoual, S. Hans, and N. Merillon et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer Cancer Res 73 1 2013 128 138
42. J. Duraiswamy, K.M. Kaluza, G.J. Freeman, and G. Coukos Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors Cancer Res 73 12 2013 3591 3603
43. L. Ni, C.J. Ma, and Y. Zhang et al. PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma Immunol Cell Biol 89 4 2011 535 539
44. W. Wang, R. Lau, D. Yu, W. Zhu, A. Korman, and J. Weber PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells Int Immunol 21 9 2009 1065 1077
45. S. Lyford-Pike, S. Peng, and G.D. Young et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma Cancer Res 2013
46. S.E. Strome, H. Dong, and H. Tamura et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Res 63 19 2003 6501 6505
47. O.C. Ukpo, W.L. Thorstad, and J.S. Lewis Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma Head Neck Pathol 7 2 2013 113 121
48. F. Zhang, Z. Liu, Y. Cui, G. Wang, and P. Cao The clinical significance of the expression of costimulatory molecule PD-L1 in nasopharyngeal carcinoma Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 22 9 2008 408 410
49. M.C. Hsu, J.R. Hsiao, and K.C. Chang et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma Mod Pathol 23 10 2010 1393 1403
50. Y.A. Cho, H.J. Yoon, J.I. Lee, S.P. Hong, and S.D. Hong Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma Oral Oncol 47 12 2011 1148 1153
51. M. Cella, F. Sallusto, and A. Lanzavecchia Origin, maturation and antigen presenting function of dendritic cells Curr Opin Immunol 9 1 1997 10 16
52. T.J. Curiel, S. Wei, and H. Dong et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nat Med 9 5 2003 562 567
53. S. Ostrand-Rosenberg, P. Sinha, D.W. Beury, and V.K. Clements Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression Semin Cancer Biol 22 4 2012 275 281
54. K. Chikamatsu, K. Sakakura, M. Toyoda, K. Takahashi, T. Yamamoto, and K. Masuyama Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck Cancer Sci 103 6 2012 976 983
55. C.T. Allen, N.P. Judd, J.D. Bui, and R. Uppaluri The clinical implications of antitumor immunity in head and neck cancer Laryngoscope 122 1 2012 144 157
56. S. Amarnath, C.M. Costanzo, and J. Mariotti et al. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1 PLoS Biol 8 2 2010 e1000302
57. L.M. Francisco, V.H. Salinas, and K.E. Brown et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells J Exp Med 206 13 2009 3015 3029
58. S. Amarnath, C.W. Mangus, and J.C. Wang et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells Sci Transl Med 3 111 2011 111ra20
59. H.B. Jie, N. Gildener-Leapman, and J. Li et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients Br J Cancer 109 10 2013 2629 2635
60. C.Y. Mu, J.A. Huang, Y. Chen, C. Chen, and X.G. Zhang High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 28 3 2011 682 688
61. J.M. Taube, R.A. Anders, and G.D. Young et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 127 2012 127 137
62. R. Hino, K. Kabashima, and Y. Kato et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma Cancer 116 7 2010 1757 1766
63. K.K. Ang, J. Harris, and R. Wheeler et al. Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 1 2010 24 35
64. D.P. Zandberg, R. Bhargava, S. Badin, and K.J. Cullen The role of human papillomavirus in nongenital cancers CA Cancer J Clin 63 1 2013 57 81
65. D. Rischin, R.J. Young, and R. Fisher et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial J Clin Oncol 28 27 2010 4142 4148
66. M.R. Posner, J.H. Lorch, and O. Goloubeva et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial Ann Oncol 22 5 2011 1071 1077
67. K.A. Schalper, V. Velcheti, and D. Carvajal et al. In situ Tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas Clin Cancer Res 2014
68. V. Velcheti, K.A. Schalper, and D.E. Carvajal et al. Programmed death ligand-1 expression in non-small cell lung cancer Lab Invest 94 1 2014 107 116
69. J.D. Powderly, H. Kluger, and Stephen et al. Biomarkers and associations with clinical activity of PD-L1 blockade in a MPDL3280A study J Clin Oncol 2013 31
70. J. Grosso, D. Horak CEI, D.M. Cardona, J.S. Simon, A.K. Gupta, and J. Cogswell Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558;ONO-4538) J Clin Oncol 31 suppl; abstr 3016 2013
71. F. Tsushima, K. Tanaka, and N. Otsuki et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma Oral Oncol 42 3 2006 268 274
72. R.S. Herbst, M. Gordon, and G. Fine et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors J Clin Oncol 2013 31
73. L. Deng, H. Liang, and B. Burnette et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice J Clin Invest 124 2 2014 687 695
74. J. Zeng, A.P. See, and J. Phallen et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas Int J Radiat Oncol Biol Phys 86 2 2013 343 349